Andrew Staron, MD

Assistant Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Andrew Staron, MD is an Assistant Professor of Medicine in Hematology & Medical Oncology at the Chobanian and Avedisian School of Medicine. He was appointed to this position after completing his residency (2015–2018) and fellowship (2019–2022) at Boston Medical Center. In his third year of fellowship, Dr. Staron was selected for the role of chief fellow. Additionally, he completed a year-long clinical and research fellowship in amyloidosis (2018–2019) at the Boston University Amyloidosis Center, under the mentorship of the director, Dr. Sanchorawala.

As a practicing hematologist at Boston Medical Center, Dr. Staron has a deep commitment to serving patients and families who are affected by various hematologic diseases and who come from diverse backgrounds, drawing upon his own upbringing in an immigrant family. His main research interest is in AL amyloidosis—a rare plasma cell disorder that leads to the accumulation of abnormal immunoglobulin light chain proteins in organs. He has been the lead author on several publications in peer-reviewed journals and given presentations related to AL amyloidosis at national and international meetings. Dr. Staron helps to oversee the clinical database at the Boston University Amyloidosis Center and is directly involved in research projects utilizing this resource. He has conducted natural history studies that described important trends in disease outcomes and explored the role of minimal residual disease assessment in AL amyloidosis. Dr. Staron is also a member of the International Society of Amyloidosis and a peer-reviewer for several journals.

Publications

  • Published 8/11/2026

    Staron A. The light chain hunt: appraising assays in AL amyloidosis. Blood Adv. 2026 Aug 11; 10(15):5348-5349. PMID: 42536398.

    Read at: PubMed

  • Published 7/20/2026

    Muchtar E, Jaffe AS, Staron A, Sanchorawala V, Landau H, Pasvolsky O, Chakraborty R, Lentzsch S, Gertz MA, Dispenzieri A. A Clinically Applicable Conversion Formula Between NT-proBNP and BNP in Light-Chain Amyloidosis. JACC CardioOncol. 2026 Aug; 8(4):437-439. PMID: 42474409.

    Read at: PubMed

  • Published 7/14/2026

    Berumen A, Staron A, Kalaitzidis G, Siddiqi OK, Gopal DM, Ruberg FL, Sanchorawala V. Evaluating AL-ISS within a BNP-based model for AL amyloidosis in the daratumumab era. Blood Adv. 2026 Jul 14; 10(13):4612-4616. PMID: 41995749.

    Read at: PubMed

  • Published 4/15/2026

    Sanchorawala V, Greatsinger A, Staron A, Berk JL, Mendelson LM, Joshi T, J Burke N, Tabatabaeepour N, Smith J, Signorovitch J. Disease burden of ATTR amyloidosis based on the SF-36® health survey. Cardiooncology. 2026 Apr 15; 12(1). PMID: 41987333.

    Read at: PubMed

  • Published 4/9/2026

    Cetin O, Staron A, Mendelson L, Joshi T, Sanchorawala V. Rare dual-clone phenomenon: concurrent ? AL amyloidosis and ? restricted B-cell lymphoproliferative disorders. Haematologica. 2026 Aug 01; 111(8):2865-2869. PMID: 41952623.

    Read at: PubMed

View All 33 Publications:   View Full Profile in BUMC

Websites

Education

  • New York Medical College, MD
  • Cornell University, BS

View all profiles